Sanofi-Aventis and FDA notified healthcare professionals of changes to the Warnings and Overdosage sections of the Prescribing Information for Norpramin (desipramine hydrochloride), indicated for the treatment of depression. The new safety information
Read More...
Read the complete post at http://www.anxietyinsights.info/fda_issues_warning_for_norpraminreg_desipramine_hydrochlo.htm
Posted
Dec 03 2009, 09:12 PM
by
Latest entries from www.anxietyinsights.info